« Is the "Big" in Big Pharma a value creator or a liability? | Main | It's All About FDA Transparency - Let the Sun Shine In »

05/23/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0134817be121970c

Listed below are links to weblogs that reference Piramal finally falls to Abbott in India:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

As reported in Medical News Today (Sept 11th) this deal has officially closed
http://www.medicalnewstoday.com/articles/200515.php

bigredbruce

Thanks for correction Ram with regard to Ranbaxy. Given their current manufacturing problems throughout their network - maybe Daiichi is closer to considering such a move! Or at least wondering why they bought the asset in the 1st place
http://bit.ly/dfFQRa

Ram

Brad, Ranbaxy has already been purchased by Daiichi. So, unless the Japs sell out, there's no buying of Ranbaxy.

bigredbruce

WSJ report on Abbott and Piramal. Says Abbott paid steep price that indicates other buyers were in competition. GSK and Sanofi both mentioned as possibles in battle for pharmerging market share.
http://bit.ly/9WjXZV

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada